Mechanisms of diabetic kidney disease and established and emerging treatments

IF 40 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Victor Martinez Leon, Rachel Hilburg, Katalin Susztak
{"title":"Mechanisms of diabetic kidney disease and established and emerging treatments","authors":"Victor Martinez Leon, Rachel Hilburg, Katalin Susztak","doi":"10.1038/s41574-025-01171-3","DOIUrl":null,"url":null,"abstract":"<p>Kidney disease is the leading cause of mortality in persons with diabetes mellitus. Diabetic kidney disease (DKD) typically presents with a reduced estimated glomerular filtration rate and, in many but not all cases, with marked proteinuria. Strict glycaemic control and blood pressure control remain foundational in managing DKD, and advances in the understanding of disease mechanisms have redefined the therapeutic landscape. Large outcome trials, such as EMPA-KIDNEY, DAPA-CKD and CREDENCE, have demonstrated that sodium–glucose cotransporter 2 inhibitors slow chronic kidney disease progression and improve cardiovascular outcomes. Glucagon-like peptide 1 receptor agonists reduce albuminuria and preserve estimated glomerular filtration rate, as shown most recently in the FLOW trial. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, lowered renal and cardiovascular risk in the FIDELIO-DKD and FIGARO-DKD trials. Combination approaches (for example, sodium–glucose cotransporter 2 inhibition plus endothelin receptor type A blockade in ZENITH-CKD), aldosterone synthase inhibition, and targeted anti-inflammatory or complement-modifying agents offer additional promise. We summarize the key pathophysiological drivers (glomerular hyperfiltration, podocyte injury, tubulointerstitial inflammation and fibrosis), review established treatments and highlight emerging strategies to prevent or halt DKD.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"17 1","pages":""},"PeriodicalIF":40.0000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41574-025-01171-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Kidney disease is the leading cause of mortality in persons with diabetes mellitus. Diabetic kidney disease (DKD) typically presents with a reduced estimated glomerular filtration rate and, in many but not all cases, with marked proteinuria. Strict glycaemic control and blood pressure control remain foundational in managing DKD, and advances in the understanding of disease mechanisms have redefined the therapeutic landscape. Large outcome trials, such as EMPA-KIDNEY, DAPA-CKD and CREDENCE, have demonstrated that sodium–glucose cotransporter 2 inhibitors slow chronic kidney disease progression and improve cardiovascular outcomes. Glucagon-like peptide 1 receptor agonists reduce albuminuria and preserve estimated glomerular filtration rate, as shown most recently in the FLOW trial. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, lowered renal and cardiovascular risk in the FIDELIO-DKD and FIGARO-DKD trials. Combination approaches (for example, sodium–glucose cotransporter 2 inhibition plus endothelin receptor type A blockade in ZENITH-CKD), aldosterone synthase inhibition, and targeted anti-inflammatory or complement-modifying agents offer additional promise. We summarize the key pathophysiological drivers (glomerular hyperfiltration, podocyte injury, tubulointerstitial inflammation and fibrosis), review established treatments and highlight emerging strategies to prevent or halt DKD.

Abstract Image

糖尿病肾病的机制和已建立的和新兴的治疗方法
肾脏疾病是糖尿病患者死亡的主要原因。糖尿病肾病(DKD)通常表现为肾小球滤过率降低,并在许多但并非所有病例中伴有明显的蛋白尿。严格的血糖控制和血压控制仍然是管理DKD的基础,对疾病机制的理解的进步重新定义了治疗前景。EMPA-KIDNEY、DAPA-CKD和CREDENCE等大型结局试验已经证明,钠-葡萄糖共转运蛋白2抑制剂可以减缓慢性肾脏疾病的进展,改善心血管结局。最近的FLOW试验显示,胰高血糖素样肽1受体激动剂可减少蛋白尿并保持肾小球滤过率。非甾体矿物皮质激素受体拮抗剂菲纳酮在FIDELIO-DKD和FIGARO-DKD试验中降低了肾脏和心血管风险。联合治疗方法(例如,在ZENITH-CKD中,钠-葡萄糖共转运蛋白2抑制加内皮素受体A型阻断)、醛固酮合成酶抑制和靶向抗炎或补体修饰剂提供了额外的希望。我们总结了关键的病理生理驱动因素(肾小球高滤过、足细胞损伤、小管间质炎症和纤维化),回顾了已有的治疗方法,并强调了预防或阻止DKD的新策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Reviews Endocrinology
Nature Reviews Endocrinology 医学-内分泌学与代谢
CiteScore
42.00
自引率
0.70%
发文量
158
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信